olivLaw · US equity research
Myomo, Inc. MYO
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842 · Vertical: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Myomo, Inc. develops and markets MyoPro, a myoelectric-controlled upper limb orthosis for people with partial arm paralysis after stroke, nerve injury or other neuromuscular conditions. The company is trying to shift revenue toward recurring patient sources, and the first half of 2026 shows revenue growth and a higher gross margin, while losses remain a point to watch.
At the close of 04 Nov 2026, Myomo, Inc. (MYO) stock was 1.30 USD (+1.56% on the day), with market capitalisation 51.5 m USD, beta 1.47, 52-week range 0.64–1.86 USD. Latest reported quarter (Q2 2026): revenue of 11.7 m USD (+21.3% YoY), net income of -4.0 m USD, diluted EPS -0.09 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 48.7
- neutral
- Bollinger (20, 2)
- 1.13 – 1.40
- in the upper half of the band · %B 0.62 · band width 21.1%
- SMA 50 / 200
- 1.40 / 1.08
- mixed trend
- MACD (12, 26, 9)
- -0.05 / -0.06
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −22.2% | −1.1% | −21.1 pp | — |
| 3 months | +22.6% | −0.5% | +23.1 pp | — |
| 6 months | +52.4% | +4.4% | +48.0 pp | — |
| Year to date | +42.9% | +12.3% | +30.5 pp | — |
| 1 year | +54.6% | +13.5% | +41.0 pp | −2.5% |
| 3 years | −5.1% | +76.4% | −81.5 pp | −0.2% |
| 5 years | −87.5% | +63.7% | −151.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.2 m | 12.1 m | 9.8 m | 9.7 m | 10.1 m | 11.4 m | 10.1 m | 11.7 m |
| Cost of revenue | 2.3 m | 3.5 m | 3.2 m | 3.6 m | 3.6 m | 3.6 m | 3.2 m | 3.3 m |
| Gross profit | 6.9 m | 8.6 m | 6.6 m | 6.1 m | 6.4 m | 7.8 m | 6.9 m | 8.4 m |
| Research & development | 1.2 m | 1.6 m | 1.8 m | 2.0 m | 1.5 m | 1.6 m | 1.6 m | 1.7 m |
| Operating income | -957.6 k | -245.3 k | -3.5 m | -4.6 m | -3.5 m | -2.8 m | -3.2 m | -2.3 m |
| Depreciation & amortisation | — | — | 158.4 k | 190.8 k ≈ | — | — | 291.6 k | 384.5 k ≈ |
| Pre-tax income | -881.5 k | -175.3 k | -3.3 m | -4.5 m | -3.5 m | -3.7 m | -2.8 m | -4.0 m |
| Income tax | 84.9 k | 84.8 k | 136.8 k | 148.2 k | 135.7 k | 83.9 k | 186.7 k | 31.4 k |
| Net income | -966.4 k | -260.1 k | -3.5 m | -4.6 m | -3.7 m | -3.8 m | -3.0 m | -4.0 m |
| Diluted EPS | -0.03 | -0.01 ≈ | -0.08 | -0.11 | -0.09 | -0.09 ≈ | -0.07 | -0.09 |
| Operating cash flow | -1.5 m ≈ | 3.4 m | -2.7 m | -8.9 m ≈ | -1.8 m ≈ | -1.1 m | -2.2 m | -1.9 m ≈ |
| Capex | 320.7 k ≈ | 860.2 k | 670.7 k | 221.5 k ≈ | 2.1 m ≈ | -1.2 m | 327.8 k | 32.4 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.4 m | 3.8 m | 7.6 m | 13.9 m | 15.6 m | 19.2 m | 32.6 m | 40.9 m |
| Revenue YoY | +56.8% | +57.0% | +97.6% | +82.7% | +12.3% | +23.7% | +69.2% | +25.7% |
| Net income | -10.3 m | -10.7 m | -11.6 m | -10.4 m | -10.7 m | -8.1 m | -6.2 m | -15.6 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | -1.89 | -1.52 | -0.28 | -0.16 | -0.37 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -422.1% | -279.1% | -152.5% | -74.9% | -68.9% | -42.3% | -19.0% | -38.1% |
| Free cash flow | -9.7 m | -10.4 m | -9.1 m | -9.9 m | -10.3 m | -6.3 m | -4.7 m | -16.3 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 14.1 m USD
- Financial debt
- 11.2 m USD
- Net debt
- -2.9 m USD
- Equity
- 11.4 m USD
- Total assets
- 38.6 m USD
- Debt / equity
- 0.98x
- Current ratio
- 3.30x
- ROE
- -86.2%
- ROA
- -38.5%
- FCF margin
- -39.7%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 7.6 m | 13.9 m | 15.6 m | 19.2 m | 32.6 m | 40.9 m | SEC (XBRL)· 09 Mar 2026verified |
| Cost of revenue | 2.6 m | 3.5 m | 5.3 m | 6.1 m | 9.4 m | 14.0 m | SEC (XBRL)· 09 Mar 2026verified |
| Gross profit | 5.0 m | 10.3 m | 10.3 m | 13.2 m | 23.2 m | 26.9 m | SEC (XBRL)· 09 Mar 2026verified |
| Research & development | 1.7 m | 2.6 m | 2.5 m | 2.6 m | 4.8 m | 6.9 m | SEC (XBRL)· 09 Mar 2026verified |
| SG&A | 13.8 m | 18.0 m | 18.4 m | 18.8 m | — | — | SEC (XBRL)· 08 Mar 2024verified |
| Operating income | -10.5 m | -10.3 m | -10.7 m | -8.2 m | -6.2 m | -14.4 m | SEC (XBRL)· 09 Mar 2026verified |
| Interest expense | 218.8 k | — | — | — | — | — | SEC (XBRL)· 10 Mar 2021verified |
| Pre-tax income | -11.6 m | -10.3 m | -10.7 m | -8.0 m | -5.8 m | -15.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Income tax | — | 88.9 k | 69.9 k | 156.0 k | 365.6 k | 504.5 k | SEC (XBRL)· 09 Mar 2026verified |
| Net income | -11.6 m | -10.4 m | -10.7 m | -8.1 m | -6.2 m | -15.6 m | SEC (XBRL)· 09 Mar 2026verified |
| Diluted EPS | — | -1.89 | -1.52 | -0.28 | -0.16 | -0.37 | SEC (XBRL)· 09 Mar 2026verified |
| Weighted average diluted shares | — | 5.8 m | 7.1 m | 29.5 m | 37.8 m | 41.9 m | SEC (XBRL)· 09 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 12.2 m | 15.5 m | 5.3 m | 6.9 m | 24.4 m | 14.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Receivables | 924.9 k | 2.0 m | 1.9 m | 2.4 m | 3.8 m | 4.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Inventories | 707.1 k | 808.3 k | 1.4 m | 1.8 m | 3.2 m | 3.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Current assets | 14.4 m | 19.1 m | 9.2 m | 13.7 m | 32.8 m | 27.6 m | SEC (XBRL)· 09 Mar 2026verified |
| Property, plant & equipment, net | 95.0 k | 275.3 k | 194.3 k | 175.8 k | 1.3 m | 2.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Total assets | 14.7 m | 20.1 m | 10.2 m | 14.6 m | 42.2 m | 38.6 m | SEC (XBRL)· 09 Mar 2026verified |
| Accounts payable | 2.8 m | 3.9 m | 3.2 m | 4.9 m | 9.0 m | 5.8 m | SEC (XBRL)· 09 Mar 2026verified |
| Short-term debt | — | — | — | — | 3.0 m | 0 | SEC (XBRL)· 05 Aug 2026verified |
| Long-term debt | — | — | — | — | 11.2 m | 11.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Current liabilities | 2.9 m | 4.3 m | 3.6 m | 5.5 m | 10.2 m | 8.3 m | SEC (XBRL)· 09 Mar 2026verified |
| Total liabilities | 3.1 m | 4.7 m | 3.8 m | 5.6 m | 17.5 m | 27.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Equity | 11.6 m † | 15.4 m † | 6.4 m † | 9.0 m † | 24.7 m † | 11.4 m † | SEC (XBRL)· 09 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.0 m | -9.5 m | -10.2 m | -6.2 m | -3.3 m | -14.5 m | SEC (XBRL)· 09 Mar 2026verified |
| Capex | 45.8 k | 326.5 k | 111.8 k | 145.8 k | 1.4 m | 1.7 m | SEC (XBRL)· 09 Mar 2026verified |
| Free cash flow | -9.1 m ≈ | -9.9 m ≈ | -10.3 m ≈ | -6.3 m ≈ | -4.7 m ≈ | -16.3 m ≈ | SEC (XBRL)· 09 Mar 2026derived |
| Investing cash flow | -45.8 k | -326.5 k | -310.8 k | -2.0 m | 260.0 k | -7.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Financing cash flow | 16.8 m | 13.2 m | 376.9 k | 9.7 m | 20.9 m | 11.4 m | SEC (XBRL)· 09 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 37.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 51.5 m USD
Key indicators
Coverage and freshness
Score by group
38% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -171.5% | 0 (vs peers) | 28% |
| Net margin · Quality | -33.5% | 36 (vs peers) | 17% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 38.1% | 100 (on a fixed band) | 22% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.3x | 100 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -16.2% | 0 (on a fixed band) | 22% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality14/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Myomo, Inc. (MYO). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 40.9 m USD in 2025; YoY growth 25.7%; net margin -33.5%; ROE -123.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 38.1%
- Current ratio: 2.3x
What contradicts it
- ROIC: -171.5%
- FCF yield: -16.2%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 167.1 bn | 58.3 | 18.0% | 25.5% | +20.5% | −16% / +55% |
| EWEdwards Lifesciences Corporation | 57.1 bn | 56.2 | 9.7% | 15.3% | +11.5% | +15% / +47% |
| SNNSmith & Nephew plc | 28.5 bn | 45.3 | 11.8% | 10.1% | +6.1% | −2% / +25% |
| STESTERIS plc | 24.2 bn | 30.0 | 11.4% | 13.3% | +8.7% | −7% / +23% |
| ZBHZimmer Biomet Holdings, Inc. | 20.8 bn | 27.9 | 6.0% | 9.0% | +7.2% | +13% / −5% |
| ALGNAlign Technology, Inc. | 11.6 bn | 24.0 | 11.9% | 11.8% | +0.9% | +12% / −23% |
| MSAMsa Safety Inc | 6.8 bn | 22.8 | 22.1% | 15.0% | +3.7% | +10% / +2% |
| ESTAEstablishment Labs Holdings Inc. | 2.0 bn | — | -175.3% | -15.8% | +27.1% | −3% / +161% |
| ENOVEnovis Corp | 1.4 bn | — | -54.3% | -48.0% | +6.7% | −19% / −51% |
| CDRECadre Holdings, Inc. | 1.3 bn | 33.8 | 11.6% | 5.6% | +7.5% | −28% / −4% |
| AVRAnteris Technologies Global Corp. | 596.4 m | — | -75.1% | -4,619.3% | −29.2% | +49% / unavailable |
| COCHEnvoy Medical, Inc. | 549.6 m | — | — | -11,304.8% | +7.1% | +749% / +216% |
| ZJYLJin Medical International Ltd. | 483.7 m | 309.0 | 4.1% | 5.8% | −12.0% | −39% / −87% |
| SMTISanara Medtech Inc. | 297.0 m | — | -147.7% | -29.2% | +19.0% | +55% / −0% |
| INGNInogen, Inc. | 191.6 m | — | -13.1% | -6.9% | +3.9% | +2% / +24% |
| LAKELakeland Industries, Inc. | 88.7 m | — | -19.6% | -14.0% | +15.2% | −41% / −39% |
| NTRBNutriband Inc. | 73.9 m | — | -100.7% | -430.4% | −4.8% | +23% / +140% |
| APTAlpha Pro Tech, Ltd. | 58.6 m | 14.1 | 6.6% | 6.8% | +2.3% | +25% / +17% |
| CLGNCollPlant Biotechnologies Ltd | 54.2 m | — | -117.6% | -484.6% | +360.4% | −81% / −92% |
| MYOMyomo, Inc. | 51.5 m | — | -123.8% | -33.5% | +25.7% | +55% / −5% |
| MLSSMilestone Scientific Inc. | 29.2 m | — | -121.7% | -44.0% | +4.0% | +6% / −61% |
| LFWDLifeward Ltd. | 17.2 m | — | -225.6% | -141.3% | −14.1% | −13% / −90% |
| CUPRCuprina Holdings (Cayman) Limited | 14.1 m | — | -1,115.0% | -9,366.7% | +9.2% | −64% / unavailable |
| BBLGBone Biologics Corporation | 1.2 m | — | -47.5% | — | 0.0% | −77% / −98% |
1- and 3-year price returns: for MYO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Myomo, Inc. develops and markets MyoPro, a myoelectric-controlled upper limb orthosis for people with partial arm paralysis after stroke, nerve injury or other neuromuscular conditions. The company is trying to shift revenue toward recurring patient sources, and the first half of 2026 shows revenue growth and a higher gross margin, while losses remain a point to watch 123.
SWOT
Strengths
Weaknesses
- The company has posted recurring net losses and relies on external financing to support operations 1.
- Revenue concentration in Medicare reimbursement and a few payers makes the company vulnerable to policy changes 1.
- The cost of acquiring patients through advertising rose in 2025, weighing on commercial efficiency 1.
Opportunities
Threats
- Changes in CMS policy or restrictions by Medicare Advantage insurers could cut revenue directly 1.
- Tariffs and rising component costs could affect production costs, although the company expects a limited impact 1.
- The bankruptcy of the Chinese partner and the termination of the joint venture show the risk of international partnerships 12.
Risks
- Reimbursement dependencehigh
Sales depend largely on insurer coverage, and post-service denials could affect cash flow 1.
- Concentration on a few payershigh
A small number of payers generate a significant part of revenue, and any change could have rapid effects 1.
- Losses and need for capitalmedium
The company has reported repeated net losses and could need additional capital if profitability goals are delayed 12.
- Tariff and supply chain risksmedium
Tariffs and rising component costs could affect gross margin, although the company estimates a limited impact 1.
- Risk in the China partnershiplow
The bankruptcy of the local partner led to termination of the joint venture, and any effects on access to external markets remain to be seen 12.
Investment thesis
What would need to be true (bull case)
- If revenue from recurring channels keeps growing, the company could lower acquisition costs and reach better operating profitability 23.
- Rising gross margin and a higher annual guidance show that the commercial model is starting to produce measurable effects 3.
- The product has patent protection and published clinical evidence, which could support clinician and payer acceptance 1.
What would break the thesis
- If Medicare Advantage insurers keep limiting authorizations, revenue growth could slow considerably 1.
- Repeated net losses and limited cash could force the company to seek costly financing again 12.
- If the reduction in cost per pipeline add does not materialize, advertising-based growth could be hard to sustain 1.
What to watch
- Delivery of the annual revenue guidance2026
- Development of recurring channels and ordersQ3 2026
- Trend in gross margin and operating expensesQ3 2026
- Results of the University of Utah randomized trialnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Myomo presents itself as a wearable medical robotics company offering functional improvement to people with neuromuscular disorders and upper limb paralysis 1. Its main product, MyoPro, is a rigid brace custom-fabricated for each user that supports a weak arm and uses the wearer's own muscle signals to aid daily activities 1. The company operates as one business segment and is headquartered in Burlington, Massachusetts 1.
The main sales channel is direct billing, in which Myomo evaluates, measures and fits the device and then bills the insurer; this channel represented 74% of product revenue in fiscal 2025 1. The company also sells through O&P providers, the Department of Veterans Affairs and some markets outside the United States, and in 2026 it aims to grow recurring channels including the MyoConnect referral program 12.
Total revenue rose 26% in fiscal 2025, but the net loss of $15.6 million shows that expansion remains costly 1. In the first half of 2026 revenue increased year over year and the company raised its annual guidance, while cash and short-term investments stood at $13.5 million at the end of June 2026 23.
Segments
Market context
The company estimates that about 6.3 million people in the United States have had a stroke, of whom 3.8 million have moderate to severe upper extremity impairment persisting 1. Only a fraction may be medically qualified for MyoPro, and Myomo says its addressable market depends on insurance coverage including Medicare Part B 1.
The market is shaped by CMS reimbursement levels, which were updated to approximately $68,800 for code L8702 effective January 1, 2026 1. Because reimbursement is still largely case by case, access could vary with payer decisions and government policy 1.
Trends
- Medicare Part B coveragemixed
Revenue from Medicare Part B patients was 54% of total revenue in 2025, showing dependence on a single payment program 1. If these reimbursements expand they could support growth, but any restriction would hit revenue directly 1. The effect is mixed, since the program gives access but also concentration.
- Growth of referral channelstailwind
Myomo reports that 53% of second quarter 2026 revenue came from recurring patient sources, up from 26% a year earlier 3. If this shift holds it could reduce reliance on costly advertising 23.
- Pressure from Medicare Advantage insurersheadwind
Medicare Advantage insurers have reduced authorizations, and revenue from those plans fell 2% in 2025 1. The company says this requires additional appeal work and could reduce revenue if the trend continues 1.
Competitive position
The supplied sources do not name listed competitors; they describe alternatives such as occupational therapy, electrical stimulation, static braces and myoelectric prostheses for amputees 1. Myomo states that MyoPro is the only device marketed in the U.S. that uses a patient's own EMG signals to restore movement 3.
Competition also comes from myoelectric prostheses, which are an alternative for amputees, and from rehabilitation therapies that form the standard of care 1. For Myomo, differentiation depends on clinical evidence, reimbursement access and its referral network 13.
- Myoelectric prostheses
The sources mention myoelectric prostheses as an alternative for amputees without naming a listed producer 1.
- Occupational and rehabilitation therapy
These form the standard of care for patients with neurological injury but are not listed companies 1.
- Electrical stimulation and static braces
The source describes these as available interventions without identifying a separate listed competitor 1.
- O&P service providers
These are distribution and fitting partners, and also a possible alternative in the value chain 13.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report (amendment)29 Jun 2026Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Current report26 Jun 2026Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Proxy statement14 May 2026
- Current report13 May 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Current report16 Apr 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Annual report09 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Myomo, Inc. · 09 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Myomo, Inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Myomo, Inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.